After listening to the Lias presentation, I am even more encouraged by the pure play CDMO strategy that the company has transitioned to. As a shareholder:
1) Big Pharma has been walking and surveying the site. We should be hearing about some new contracts and revenue that will get us to a minimum of $100M in revenue this year. And that is just the beginning.
2) However residual value is defined, be it milestones or CVR's or licensing, it will help the share price. These guys are smart and will extract whatever value is there. Just nonsense that they don't understand their assets.
3) There will be a capital raise (and will probably be a hybrid structure). However, the big difference is that there will be a defined return on that investment-no longer dilution just to fund board salaries.
Market Data 
Markets 
AI
